The Association for Accessible Medicines (AAM), Washington, D.C., is a trade association representing the manufacturers and distributors of generic prescription drugs, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the U.S. generic drug industry.
[5] In 2004, GPhA began promoting the potential benefits of developing a market for biosimilar versions of biologic therapies and provided answers to questions that the FDA posed in a September 2004 workshop on the scientific challenges of creating biosimilars.
[6] On May 2, 2007, GPhA's then-Chairman Bruce Downey testified before the House Energy and Commerce Committee Subcommittee on Health, urging Congress to pass legislation giving FDA the authority to approve biosimilars.
[7] Congress created an approval pathway for biosimilars (including interchangeables that are substitutable with their reference product) with passage of the Biologics Price Competition and Innovation Act, part of the Patient Protection and Affordable Care Act signed by President Obama on March 23, 2010.
He succeeds Chester "Chip" Davis, Jr. who is now the President and Chief Executive Officer of the Healthcare Distribution Alliance.